Patents by Inventor Jan UNGEWIß

Jan UNGEWIß has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF
    Publication number: 20240335569
    Abstract: The present invention is related to a compound of Formula (I)
    Type: Application
    Filed: July 22, 2022
    Publication date: October 10, 2024
    Applicant: 3 B PHARMACEUTICALS GMBH
    Inventors: Frank OSTERKAMP, Dirk ZBORALSKI, Matthias PASCHKE, Aileen HÖHNE, Jessica WAHSNER-TESCHNER, Christian HAASE, Ulrich REINEKE, Christiane SMERLINE, Jan UNGEWIß, Anne BREDENBECK, Christoph GIBSON, Jörn SAUPE
  • COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF
    Publication number: 20230212549
    Abstract: The present invention is related to a compound comprising a cyclic peptide of formula (I) and an N-terminal modification group A attached to Xaa1, wherein each and any one of Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6 and Xaa7 is a residue of an amino acid, and Yc is a structure of formula (X)
    Type: Application
    Filed: January 7, 2022
    Publication date: July 6, 2023
    Applicant: 3B PHARMACEUTICALS GMBH
    Inventors: Frank OSTERKAMP, Dirk ZBORALSKI, Eberhard SCHNEIDER, Christian HAASE, Matthias PASCHKE, Aileen HÖHNE, Jan UNGEWIß, Christiane SMERLING, Ulrich REINEKE, Anne BREDENBECK, Jan Lennart von Hacht
  • COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF
    Publication number: 20220315554
    Abstract: The present invention is related to a compound comprising a cyclic peptide of formula (I) and an N-terminal modification group A attached to Xaa1, wherein each and any one of Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6 and Xaa7 is a residue of an amino acid, and Yc is a structure of formula (X)
    Type: Application
    Filed: July 8, 2020
    Publication date: October 6, 2022
    Applicant: 3B PHARMACEUTICALS GMBH
    Inventors: Frank OSTERKAMP, Dirk ZBORALSKI, Eberhard SCHNEIDER, Christian HAASE, Matthias PASCHKE, Aileen HÖHNE, Jan UNGEWISS, Christiane SMERLING, Ulrich REINEKE, Anne BREDENBECK
  • COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF
    Publication number: 20220273831
    Abstract: The present invention is related to a compound comprising a cyclic peptide and a chelator, and its use.
    Type: Application
    Filed: July 8, 2020
    Publication date: September 1, 2022
    Inventors: Frank OSTERKAMP, Dirk ZBORALSKI, Eberhard SCHNEIDER, Christian HAASE, Matthias PASCHKE, Aileen HÖHNE, Jan UNGEWISS, Christiane SMERLING, Ulrich REINEKE, Anne BREDENBECK
  • Neurotensin receptor ligands
    Patent number: 10961199
    Abstract: The present invention is related to a compound of formula (I) wherein R1 is selected from the group consisting of hydrogen, methyl and cyclopropylmethyl; AA-COOH is an amino acid selected from the group consisting of 2-amino-2-adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.1]nonane-9-carboxylic acid; R2 is selected from the group consisting of (C1-C6)alkyl, (C3-C8)cycloalkyl, (C3-C5)cycloalkylmethyl, halogen, nitro and trifluoromethyl; ALK is (C2-C5)alkylidene; R3, R4 and R5 are each and independently selected from the group consisting of hydrogen and (C1-C4)alkyl under the proviso that one of R3, R4 and R5 is of the formula (II) wherein ALK? is (C2-C5)alkylidene; R6 is selected from the group consisting of hydrogen and (C1-C4)alkyl; and R7 is selected from the group consisting of H and an Effector moiety; or a pharmacologically acceptable salt, solvate or hydrate thereof.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: March 30, 2021
    Assignee: 3B PHARMACEUTICALS GMBH
    Inventors: Frank Osterkamp, Christiane Smerling, Ulrich Reineke, Christian Haase, Jan Ungewiß
  • NEUROTENSIN RECEPTOR LIGANDS
    Publication number: 20210087149
    Abstract: The present invention is related to a compound of formula (I) wherein R1 is selected from the group consisting of hydrogen, methyl and cyclopropylmethyl; AA-COOH is an amino acid selected from the group consisting of 2-amino-2-adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.1]nonane-9-carboxylic acid; R2 is selected from the group consisting of (C1-C6)alkyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkylmethyl, halogen, nitro and trifluoromethyl; ALK is (C2-C5)alkylidene; R3, R4 and R5 are each and independently selected from the group consisting of hydrogen and (C1-C4)alkyl under the proviso that one of R3, R4 and R5 is of the formula (II) wherein ALK? is (C2-C5)alkylidene; R6 is selected from the group consisting of hydrogen and (C1-C4)alkyl; and R7 is selected from the group consisting of H and an Effector moiety; or a pharmacologically acceptable salt, solvate or hydrate thereof.
    Type: Application
    Filed: December 4, 2020
    Publication date: March 25, 2021
    Applicant: 3B Pharmaceuticals
    Inventors: Frank OSTERKAMP, Christiane SMERLING, Ulrich REINEKE, Christian HAASE, Jan UNGEWIß
  • Conjugate comprising a neurotensin receptor ligand and use thereof
    Patent number: 10799605
    Abstract: The present invention is related to a conjugate comprising a structure of general formula (1) [TM1]-[AD1]-[LM]-[AD2]-[TM2] (1), wherein TM1 is a first targeting moiety, wherein the first targeting moiety is capable of binding to a first target, AD1 is a first adapter moiety or is absent, LM is a linker moiety or is absent, AD2 is a second adapter moiety or is absent, and TM2 is a second targeting moiety, wherein the second targeting moiety is capable of binding to a second target; wherein the first targeting moiety and/or the second targeting moiety is a compound of formula (2): wherein R1 is selected from the group consisting of hydrogen, methyl and cyclopropylmethyl; AA-COOH is an amino acid selected from the group consisting of 2-amino-2 adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: October 13, 2020
    Assignee: 3B Pharmaceuticals GMBH
    Inventors: Frank Osterkamp, Christian Haase, Ulrich Reineke, Christiane Smerling, Matthias Paschke, Jan Ungewiß
  • CONJUGATE COMPRISING A NEUROTENSIN RECEPTOR LIGAND AND USE THEREOF
    Publication number: 20170119913
    Abstract: The present invention is related to a conjugate comprising a structure of general formula (1) [TM1]-[AD1]-[LM]-[AD2]-[TM2] (1), wherein TM1 is a first targeting moiety, wherein the first targeting moiety is capable of binding to a first target, AD1 is a first adapter moiety or is absent, LM is a linker moiety or is absent, AD2 is a second adapter moiety or is absent, and TM2 is a second targeting moiety, wherein the second targeting moiety is capable of binding to a second target; wherein the first targeting moiety and/or the second targeting moiety is a compound of formula (2): wherein R1 is selected from the group consisting of hydrogen, methyl and cyclopropylmethyl; AA-COOH is an amino acid selected from the group consisting of 2-amino-2 adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.
    Type: Application
    Filed: June 10, 2015
    Publication date: May 4, 2017
    Inventors: Frank Osterkamp, Christian Haase, Ulrich Reineke, Christiane Smerling, Matthias Paschke, Jan Ungewiß
  • NEUROTENSIN RECEPTOR LIGANDS
    Publication number: 20150299133
    Abstract: The present invention is related to a compound of formula (I) wherein R1 is selected from the group consisting of hydrogen, methyl and cyclopropylmethyl; AA-COOH is an amino acid selected from the group consisting of 2-amino-2-adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.1]nonane-9-carboxylic acid; R2 is selected from the group consisting of (C1-C6)alkyl, (C3-C8)cycloalkyl, (C3-C5)cycloalkylmethyl, halogen, nitro and trifluoromethyl; ALK is (C2-C5)alkylidene; R3, R4 and R5 are each and independently selected from the group consisting of hydrogen and (C1-C4)alkyl under the proviso that one of R3, R4 and R5 is of the formula (II) wherein ALK? is (C2-C5)alkylidene; R6 is selected from the group consisting of hydrogen and (C1-C4)alkyl; and R7 is selected from the group consisting of H and an Effector moiety; or a pharmacologically acceptable salt, solvate or hydrate thereof.
    Type: Application
    Filed: December 6, 2013
    Publication date: October 22, 2015
    Inventors: Frank OSTERKAMP, Christiane SMERLING, Ulrich REINEKE, Christian HAASE, Jan UNGEWIß